Business Update Positive

2026-10-03 17:04

Aurobindo Pharma received USFDA final approval for Perampanel Tablets (2 mg to 12 mg). - The product has an estimated market size of US$ 67 million for the twelve months ending August 2026. - Launch is scheduled for Q3 FY27 from Unit-IV of APL Healthcare. - Total ANDA approvals for the company now stand at 599.

Business Update Positive

2026-10-02 18:33

- Aurobindo Pharma announced that its wholly-owned subsidiary, Apitoria Pharma Private Limited, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. - Apitoria now holds an 80% ownership stake in A1 Labs India, with the remaining 20% held by Dr. Rajendra Gadikota. - A1 Labs India's wholly-owned US subsidiary has acquired 100% membership interest in A1 Biochem Labs LLC, USA. - The acquisition provides access to an established CRO platform with over 50 clients and 800+ completed projects, expanding Apitoria into an integrated CRDMO platform.

Business Update Positive

2026-10-02 18:08

- Aurobindo Pharma's subsidiary, Apitoria Pharma, through its subsidiary A1 Labs India and A1 USA Inc, has acquired 100% ownership of A1 Biochem Labs LLC, USA. - The acquisition cost is USD 15.247 million in cash. - A1 Labs LLC provides contract research and chemistry services and had a turnover of USD 5.92 Million in CY2025. - The acquisition aligns with the company's objective to build a dedicated CRDMO platform and expand its API business life cycle.

Business Update Neutral

2026-10-01 12:49

- Aurobindo Pharma's subsidiary, Apitoria Pharma, diluted its 100% stake in A1 Biochem Labs by issuing 20% stake (equity shares and CCDs) to former promoter Dr. Rajendra Gadikota for ₹33.80 Cr on September 30, 2026. - A1 Labs remains a step-down subsidiary of Aurobindo Pharma with Apitoria holding an 80% stake. - Apitoria holds an option to acquire the 20% stake in the future.

Business Update Positive

2026-09-30 21:27

Aurobindo Pharma announced that its step-down subsidiary, Acrotech Biopharma, has launched ADQUEY (difamilast) 1% ointment in the U.S. and established a dedicated dermatology business unit. - ADQUEY is a non-steroidal topical PDE4 inhibitor for mild-to-moderate atopic dermatitis in adults and pediatric patients aged 2 years and older. - The U.S. atopic dermatitis market for the product category is estimated at approximately US$ 1.3 billion based on IQVIA MAT data for the twelve months ending July 2026.

Routine Neutral

2026-09-29 16:39

- Appellate Joint Commissioner (ST) confirmed a tax demand against Aurobindo Pharma for FY 2020-21. - Total demand includes ITC reversal of ₹2.56 crore, interest of ₹1.78 crore, and a penalty of ₹25.65 lakh (Total: ₹4.60 crore). - The company stated there is no material impact on financials and intends to file an appeal before the GST Appellate Tribunal.

Routine Neutral

2026-09-24 10:52

- Trading window for dealing in securities of the company will remain closed with effect from October 1, 2026. - Closure remains until 48 hours after the declaration of Q2 and H1 financial results for the period ending September 30, 2026. - Date of the Board Meeting will be intimated in due course.

Business Update Neutral

2026-09-21 16:05

- Investor/Analyst Meeting Schedule - Meeting Date: September 24, 2026 - Meeting Time: 02:30 PM to 03:30 PM (IST) - Meeting with: JP Morgan Healthcare Trip - Hyderabad (Group meeting)

Business Update Neutral

2026-09-15 18:13

- US FDA inspected Aurobindo Pharma's subsidiary, Apitoria Pharma Private Limited's Unit-II API manufacturing facility from September 7th to 15th, 2026. - The inspection concluded with one observation, which is procedural in nature. - The company will respond to the US FDA within the stipulated timeline.

Business Update Positive

2026-09-15 13:05

- Aurobindo Pharma received USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol (40 mcg & 80 mcg). Its first metered-dose inhaler (MDI) product expands into complex respiratory therapies. The US market for this product was estimated at US$301 million. Launch is expected in upcoming quarters.

Business Update Positive

2026-09-12 12:43

- Aurobindo Pharma's step-down subsidiary subscribed to 10,000 equity shares of USD 100 each (total USD 1,000,000) in 'A1 Biochem USA Inc' on September 11, 2026. - This grants 100% shareholding in the newly incorporated US entity. - A1 Biochem USA Inc will undertake Contract Research and Development services.

Business Update Positive

2026-09-11 17:33

- US FDA inspected Unit-IV of Apitoria Pharma Private Limited, a wholly-owned subsidiary, from September 07 to September 11, 2026. - The inspection concluded with zero observations, indicating robust quality and compliance standards.

Business Update Neutral

2026-09-11 16:44

- Investor Meeting Schedule - Meeting Date: September 21, 2026 - Meeting Time: 09:00 AM to 5:00 PM (HKT) - Investor/Meeting name: Bank of America 2026 Asia Pacific Conference - Type of meeting: One-on-One and Group Meetings - Location: Hongkong

Business Update Neutral

2026-09-11 16:44

- Concall Schedule - Concall Date: September 22, 2026 - Concall Time: 09:00 AM to 5:00 PM (IST) - Event: J. P. Morgan India Investor Conference (One-on-One and Group Meetings)

Business Update Neutral

2026-09-11 16:40

- Investor/Analyst Meeting Schedule - Meeting Date: September 17, 2026 - Meeting Time: 10:00 AM to 11:00 AM (IST) - Type of Meeting: Group Meeting arranged by Emkay Global - Location: Hyderabad

Business Update Neutral

2026-09-11 13:09

- Concall Schedule - Concall Date: September 18, 2026 - Concall Time: 09:00 AM to 05:00 PM (IST)

Business Update Neutral

2026-09-11 13:07

- Concall Schedule - Concall Date: September 17, 2026 - Concall Time: 02:30 PM to 03:30 PM (IST) - Meeting with: ICICI Securities (Group meeting)

Business Update Positive

2026-09-01 10:11

- Aurobindo Pharma Limited's wholly-owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly-owned subsidiary named 'Avogent Lifesciences Private Limited' on August 31, 2026. - The new subsidiary will undertake manufacturing and marketing operations in India and foreign countries. - Initial share capital subscription is ₹50 Cr.

Business Update Positive

2026-08-31 10:11

- Aurobindo Pharma's wholly-owned subsidiary, Lannett Company LLC, has launched the generic version of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market. - This is the first product from the company's inhalation pipeline to be commercialized in the US.

Business Update Neutral

2026-08-28 15:38

- US FDA inspected Aurobindo Pharma's wholly-owned subsidiary Apitoria Pharma Private Limited's Unit-VI (API manufacturing facility) from August 24-28, 2026. - The inspection concluded with three observations, stated to be "procedural in nature." - The Company will respond to the US FDA within the stipulated timeline.

Governance Positive

2026-08-28 15:16

- Voting results of the 39th Annual General Meeting (AGM) held on August 27, 2026. - All resolutions were approved by shareholders with requisite majority. - Resolutions included adoption of financial statements, re-appointment of directors, appointment of secretarial auditors, and confirmation of interim dividend of ₹4/- per equity share for FY 2025-26.

Business Update Neutral

2026-08-25 17:24

- Concall Schedule - Concall Date: September 1-2, 2026 - Concall Time: 09:00 AM to 05:00 PM (HKT) - Event: Goldman Sachs Asia Leaders Conference Hong Kong 2026 - Meeting Type: One-on-one and Group meetings

Business Update Neutral

2026-08-25 14:35

- Investor/Analyst Meeting Schedule - Date: September 01, 2026 - Time: 09:00 AM to 05:00 PM (IST) - Event: ASHWAMEDH - Elara India Dialogue 2026 - Type: One-on-one and Group meetings - Location: Mumbai - No Unpublished Price Sensitive Information (UPSI) will be discussed.

Business Update Neutral

2026-08-24 09:03

- Aurobindo Pharma's step-down subsidiary, Lannett Company LLC, underwent a routine US FDA inspection from Aug 17-21, 2026. - The inspection concluded with four observations, which are procedural in nature. The company will respond as required.

Business Update Positive

2026-08-21 15:35

- US FDA completed routine inspection at Auro Peptides Ltd (subsidiary) from Aug 17-21, 2026. - Concluded with one observation on facility/equipment maintenance, not related to data integrity or GMP compliance. - Corrective actions were initiated.

Business Update Positive

2026-08-17 07:35

- US FDA inspection at Aurobindo's Raleigh Plant (via Aurolife Pharma LLC) is closed, classified as "Voluntary Action Indicated" (VAI). - This allows pending applications for multiple inhalers and other dosage forms to progress through the USFDA review process.

Business Update Neutral

2026-08-14 16:38

- Investor/Analyst Meeting Schedule - Date: August 19, 2026 - Time: 09:00 AM to 05:00 PM (IST) - Event: Motilal Oswal 22nd Annual Global Investor Conference, 2026 - Location: Mumbai - Type: One-on-one and Group meetings

Business Update Negative

2026-08-14 09:39

CRITICAL RED FLAG DETECTED

- Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd. (Unit I), received a US FDA Warning Letter after being classified as Official Action Indicated (OAI). - The company states no impact on existing US market supplies; Unit I contributes ~2% to overall group revenue. - The company is committed to working with the US FDA for compliance.

Business Update Positive

2026-08-13 18:08

- Management reiterated FY27 guidance of double-digit revenue growth with EBITDA margins north of 21% and absolute EBITDA in excess of ₹8000 Cr, with potential upside. - Q1 FY27 consolidated revenues grew 16% YoY to ₹9,150 Cr. Operating EBITDA was ₹1,924 Cr with a 21% margin. PAT was ₹1,032 Cr. - Lannett acquisition successfully completed, strengthening the US platform and expected to generate SGA, operational, and procurement synergies. Advair launch planned for August. - Biosimilar pipeline progressing with imminent US filings this year, successful ANVISA inspection, and multiple EU/UK/Canada filings on track (7-8 products by FY28-29). - TheraNym Unit One for contract manufacturing is set to begin steady revenue streams from 2028, with both Unit One and Unit Two targeting $150-200 million in revenue by 2032 at 35-50% EBITDA margins. - The recently acquired A1 Biochem (CRO business) with ~₹100 Cr turnover is expected to see 3-5x growth in 3-5 years, fast-tracking Aurobindo's integrated CRDMO capabilities. - China OSD facility doubled production over the last 12 months, aiming for over 2 billion tablets capacity by mid-FY28, and is expected to become EBITDA positive. - R&D expenses for FY27 are guided around ₹1,450-1,500 Cr, a reduction due to completion of Phase 3 clinical studies for biosimilars.

Business Update Positive

2026-08-13 16:33

- Aurobindo Pharma Limited incorporated a new wholly-owned subsidiary, 'Auropharm Overseas Limited', on August 13, 2026. - The subsidiary, incorporated in India, is in the Pharmaceuticals industry. - Its object is to undertake manufacturing and marketing operations in India and foreign countries with an initial investment of ₹10,00,000.

Business Update Neutral

2026-08-06 18:12

- Concall Schedule - Concall Date: August 11 to 13, 2026 - Concall Time: 09:00 AM to 06:00 PM (GMT +8) - Event: Nuvama India Conference 2026 (in-person and group meetings in Singapore & Hong Kong)

Business Update Positive

2026-08-05 20:14

- Aurobindo Pharma's Board approved the merger of two step-down subsidiaries (Eugia Steriles Private Limited, Eugia SEZ Private Limited) with its wholly-owned subsidiary (Eugia Pharma Specialities Limited). - Rationale: To simplify the group structure, reduce costs, eliminate overheads, improve treasury management, and achieve synergy benefits. All entities manufacture injectable pharmaceutical products.

Financials Positive

2026-08-05 20:02

- Consolidated Revenue ₹9,150 Cr vs ₹7,868 Cr (▲16.3% YoY) - EBITDA ₹1,924 Cr vs ₹1,603 Cr (▲20.0% YoY) - PAT ₹1,032 Cr vs ₹824 Cr (▲25.2% YoY) - EBITDA Margin 21.0% vs 20.4% (▲60bps)

Financials Positive

2026-08-05 19:49

- Consolidated Revenue ₹9,105.82Cr vs ₹7,791.77Cr (▲16.86% YoY) - EBITDA ₹1,839.34Cr vs ₹1,604.95Cr (▲14.60% YoY) - PAT ₹1,032.03Cr vs ₹824.20Cr (▲25.22% YoY) - EBITDA Margin 20.20% vs 20.59% (▼39bps) - The Board approved a scheme of amalgamation for the merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited with Eugia Pharma Specialities Limited. - The company completed the acquisition of 100% membership interest in Lannett Company LLC and its subsidiaries for USD 247.1 million on June 29, 2026, which impacts comparability of results with previous periods.

Governance Neutral

2026-08-04 11:29

- Intimation of the 39th Annual General Meeting (AGM) to be held on Thursday, August 27, 2026, at 3:30 p.m. IST via Video Conferencing/OAVM. - The web-link for the Integrated Annual Report 2025-26 and AGM Notice has been provided to shareholders. - E-voting will commence on August 24, 2026, at 9:00 a.m. IST and conclude on August 26, 2026, at 5:00 p.m. IST, with a cut-off date of August 20, 2026.

Governance Neutral

2026-08-03 19:01

- Notice of 39th Annual General Meeting (AGM) to be held on Thursday, August 27, 2026, at 3:30 p.m. IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). - Agenda includes adoption of Audited Standalone and Consolidated Financial Statements for FY ended March 31, 2026, confirmation of interim dividend of ₹4.00 per equity share for FY 2025-26, re-appointment of directors, and appointment of Secretarial Auditor.

Governance Neutral

2026-07-29 16:55

- The 39th Annual General Meeting (AGM) will be held on Thursday, August 27, 2026, at 3:30 p.m. IST via Video Conferencing. - The Register of Members and Share Transfer Books will remain closed from August 26-27, 2026, for the AGM purpose.

Business Update Neutral

2026-07-29 11:08

- Concall Schedule for Q1FY27 Unaudited Financial Results - Concall Date: August 06, 2026, Thursday - Concall Time: 8:30 AM IST

Business Update Positive

2026-07-24 21:48

- Aurobindo Pharma signed a royalty-free, non-exclusive voluntary license agreement with MSD (Merck & Co., Inc.). - The agreement enables Aurobindo to supply generic alimatravir for HIV prevention to 129 Low- & Middle-Income Countries.

Business Update Positive

2026-07-23 21:36

- Aurobindo Pharma's subsidiary, Apitoria, to acquire 80% of A1 Biochem Group's CRO business for USD 17 million. - Aims to expand API business and create a CRDMO platform. - A1 Biochem Group reported FY26 turnover of INR 1,024.42 Mn and EBITDA of INR 465.46 Mn. - Expected completion in 90-120 days via cash consideration.

Business Update Positive

2026-07-21 16:37

- Aurobindo Pharma's subsidiary, CuraTeQ Biologics, received ANVISA approval for its Hyderabad biosimilars manufacturing facility. - This approval strengthens the company's capability to supply biosimilar products to Brazilian and broader Latin American markets.

Business Update Positive

2026-07-10 13:10

- Aurobindo Pharma Limited's wholly-owned step-down subsidiary, PT Aurogen Pharma Indonesia, has incorporated a new wholly-owned subsidiary company named PT Auro Pharm Indonesia in Indonesia. - Incorporated on July 1, 2026, the new entity will undertake manufacturing operations. - Aurobindo acquired 100% shareholding with an initial subscription of IDR 20,000,000,000.

Business Update Neutral

2026-07-02 10:39

- Aurobindo Pharma Limited completed the transfer of its domestic branded generic pharmaceutical formulations products business to its wholly-owned subsidiary, Auropharm Limited. - The business transfer was effective from July 1, 2026, on a slump sale basis.

Business Update Positive

2026-06-30 10:00

- Aurobindo Pharma USA Inc. successfully completed the acquisition of Lannett Company, Inc. USA. - Lannett became a wholly owned subsidiary of APUSA effective June 29, 2026, strengthening APUSA's talent base with over 400 employees and operational capabilities.

Business Update Neutral

2026-06-27 10:39

- US FDA inspected Auroactive Pharma Private Limited (a wholly owned subsidiary) from June 22, 2026, to June 26, 2026. - The inspection concluded with 2 observations, which the company will respond to within the stipulated time. - The company confirmed there is no impact on its financials or operations due to the said action.

Business Update Positive

2026-06-25 18:44

- Aurobindo Pharma completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited on June 25, 2026. - The company made an initial investment of Rs. 52 lakhs to purchase solar power for captive consumption.

Routine Neutral

2026-06-25 15:21

- Trading Window for designated persons will be closed from July 1, 2026. - This closure is until 48 hours after the declaration of Q1 FY27 financial results (quarter ending June 30, 2026). - Board meeting date for results will be announced later.

Business Update Positive

2026-06-22 07:32

- Aurobindo Pharma USA (a wholly-owned subsidiary) received FTC approval to acquire Lannett Company LLC. - The transaction is valued at $250 million and is expected to close before the end of June 2026. - The acquisition will expand Aurobindo USA's product offering, add a U.S.-based manufacturing facility, and is anticipated to be immediately accretive to the Aurobindo Group's earnings per share.

Business Update Negative

2026-06-19 21:13

CRITICAL RED FLAG DETECTED

- US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles Private Limited, a 100% stepdown subsidiary, from June 10 to June 19, 2026. - The inspection concluded with 5 observations, which will be responded to within the stipulated time. - The company states there is no impact on its financials or operations due to the said action.

Business Update Positive

2026-06-19 08:29

- Aurobindo Pharma USA Inc. received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of 100% membership interest in Lannett Company LLC. - The transaction is anticipated to close before the end of June 2026.

Business Update Negative

2026-06-12 18:14

CRITICAL RED FLAG DETECTED

- US FDA classified inspection of Aurobindo Pharma's subsidiary, Eugia Pharma Specialities' Unit-III, as 'Official Action Indicated' (OAI). - The inspection (Jan 27 - Feb 06, 2026) concluded with 11 observations. - The company states no impact on its financials or operations due to this action.

Business Update Neutral

2026-06-09 15:04

- Concall Schedule - Concall Date: June 12, 2026 - Concall Time: 03:30 PM to 05:00 PM (IST) - Investor/Meeting: Goldman Sachs CRO/CDMO Tour (Group meeting)

Business Update Neutral

2026-06-05 12:44

- Investor Meeting Schedule - Meeting Date: June 10, 2026 - Meeting Time: 19:00 to 20:00 (IST) - Details: Aurobindo Pharma Limited officials will participate in a Group meeting at the UBS - Virtual Generics and Biosimilar Day (Virtual). No unpublished price sensitive information (UPSI) will be discussed.

Business Update Positive

2026-06-04 18:15

- Aurobindo Pharma received final US FDA approval for Tofacitinib Tablets, 5 mg and 10 mg. - The drug is bioequivalent and therapeutically equivalent to Xeljanz Tablets. - The estimated US market size for Tofacitinib Tablets was approximately US$494 million for the twelve months ending April 2026. - The product will be launched immediately.

Business Update Positive

2026-06-03 17:44

- Aurobindo Pharma inaugurated TheraNym, India's large-scale biologics contract manufacturing facility, on June 3, 2026. - This represents a strategic foray into biologics contract manufacturing, with MSD joining as its anchor customer. - The facility in Borapatla, Hyderabad, is equipped with 15 KL bioreactors and advanced processing capabilities.

Business Update Neutral

2026-06-03 10:57

- Investor Meeting Schedule - Meeting Date: June 8, 2026 - Meeting Time: 10:00 to 18:00 (IST) - Event: ICICI Securities India Investor Conference (In-person & Group Meetings) - Location: Mumbai

Business Update Positive

2026-05-27 18:26

Aurobindo Pharma Limited reported an excellent Q4 FY26 and strong financial year, achieving highest-ever revenues and EBITDA. For FY26, revenues reached ₹33,653 crores (▲6% YoY), and EBITDA ₹6,856 crores (▲4% YoY), with a healthy EBITDA margin of 20.4%. Net profit increased by 2% YoY to ₹921 crores for the quarter. The company expects FY27 EBITDA margins to progressively improve to north of 21%. Key growth drivers include: US business aiming for $2 billion revenue in the near term, European formulations targeting minimum double-digit growth in constant currency after achieving €1 billion in FY26. The Biosimilars business expects revenues from Unit-1 in 2028 and Unit-2 in 2031, targeting 7-8 products in Europe and growth markets and 2-3 in US by 2030, with gross margins of 65-75%. The CDMO unit also projects revenues from 2028. Pen-G and 6-APA businesses showed positive EBITDA contribution in Q4 FY26, with external sales initiated. India business is expected to grow double-digit.

Business Update Neutral

2026-05-27 16:04

Aurobindo Pharma Limited announced its officials will participate in a group meeting during the Investec US Pharma and Healthcare Bus Tour 7.0 on June 4, 2026, from 13:00 to 15:00 EDT in New Jersey, USA. The company stated that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Business Update Neutral

2026-05-27 16:01

Aurobindo Pharma Limited announced its participation in the BofA 2026 India Conference on June 2, 2026, from 9:00 AM to 6:00 PM IST in Mumbai. The company officials will engage in in-person and group meetings, and confirmed that no unpublished price sensitive information (UPSI) will be discussed.

Business Update Neutral

2026-05-25 18:28

Aurobindo Pharma Limited announced its participation in the Trinity India 2026 - 16th Annual Global Investor Conference, arranged by 360 ONE Capital. Company officials will attend in-person and group meetings in Mumbai on May 29, 2026, from 09:00 AM to 06:00 PM (IST). The company clarified that no unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

Business Update Negative

2026-05-24 17:39

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited's Unit-I formulation manufacturing facility received an "Official Action Indicated" (OAI) classification from the US FDA. The inspection, conducted from February 16-27, 2026, initially concluded with 4 observations. The company stated there is no immediate impact on its financials or operations due to this action.

Business Update Positive

2026-05-22 12:35

Aurobindo Pharma Limited's wholly-owned step-down subsidiary, Agile Pharma BV, has incorporated a new wholly-owned subsidiary, Arrow Pharma Production SAS, in France on May 21, 2026. The new entity, with an authorized capital of 100,000 EUR, will focus on expanding the manufacturing of generic formulations in France.

Governance Neutral

2026-05-21 21:10

Aurobindo Pharma Limited announced the re-appointment of M/s. Ernst & Young LLP as its Internal Auditors for the period from June 2026 to May 2027. The re-appointment was approved by the Board of Directors at their meeting held on May 21, 2026.

Governance Negative

2026-05-21 21:05

CRITICAL RED FLAG DETECTED

Aurobindo Pharma announced the resignation of M/s. MRR & Associates as its Secretarial Auditor, effective May 22, 2026, due to health issues of its sole proprietor. Concurrently, the Board approved the appointment of M/s. RPR & Associates as the new Secretarial Auditor for a five-year term, commencing from FY 2026-27 to FY 2030-31, subject to shareholder approval at the ensuing Annual General Meeting.

Governance Neutral

2026-05-21 20:54

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced the resignation of M/s. MRR & Associates as Secretarial Auditor effective May 22, 2026, citing health issues of its sole proprietor. Concurrently, the Board approved the appointment of M/s. RPR & Associates as the new Secretarial Auditors for a five-year term commencing from FY 2026-27, subject to shareholder approval.

Financials Positive

2026-05-21 20:46

Consolidated Revenue from Operations was ₹8,853 Cr vs ₹8,382 Cr (▲5.6% YoY), EBITDA was ₹1,801 Cr vs ₹1,792 Cr (▲0.5% YoY), and Net Profit was ₹921 Cr vs ₹903 Cr (▲2.0% YoY). EBITDA Margin was 20.3% vs 21.4% (▼104 bps). The company received final approval for 9 ANDAs from the USFDA during the quarter. Strong growth was noted in European and Growth Markets businesses, offsetting a decline in US revenue.

Financials Neutral

2026-05-21 19:44

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹8,853.34 Cr vs ₹8,382.12 Cr (▲5.62% YoY), EBITDA ₹1,869.82 Cr vs ₹1,926.73 Cr (▼2.95% YoY), PAT ₹920.84 Cr vs ₹902.83 Cr (▲1.99% YoY). EBITDA Margin 21.12% vs 22.98% (▼186bps). The Board also approved the resignation of Secretarial Auditors M/s. MRR & Associates and appointed M/s. RPR & Associates as their replacement for a term of five years.

Governance Negative

2026-05-16 21:42

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced that on May 6, 2026, the Hon'ble High Court of Telangana dismissed a writ petition filed by its promoter/promoter group members. The petition challenged a SEBI communication from October 23, 2020, which directed them to deposit ₹6.53 crores plus interest into the Investor Protection and Education Fund for alleged insider trading profits. The company states there is no impact on its financials or operations.

Business Update Positive

2026-05-16 09:51

Aurobindo Pharma Limited's wholly-owned subsidiary, CuraTeQ Biologics Private Limited, received CDSCO Marketing Authorisation (Form CT 23) for Bevqolva®, a Bevacizumab biosimilar. This authorization permits the manufacture and marketing of Bevqolva® (100 mg/4mL and 400 mg/16 mL vial presentations) for metastatic carcinoma of the colon or rectum, to be produced at CuraTeQ's facility in Hyderabad.

Ownership Positive

2026-05-15 19:02

Aurobindo Pharma Limited announced the extinguishment of 5,423,728 fully paid-up equity shares on May 14, 2026, following a buyback through the tender offer route at ₹1,475 per share, totaling up to ₹800 crore. This reduces the company's total issued, subscribed, and fully paid-up share capital from 58,08,01,623 to 57,53,77,895 equity shares.

Business Update Neutral

2026-05-14 16:04

Aurobindo Pharma Limited announced an earnings call to be held on May 22, 2026, at 8:30 AM IST, to discuss its Audited Financial Results for the fourth quarter and year ended March 31, 2026 (Q4 FY26). An earnings presentation will be made available on the company's website post results announcement.

Business Update Positive

2026-05-06 09:14

Aurobindo Pharma announced that its Unit-VII, an oral solid dosage manufacturing unit, received an Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated" (VAI). This follows a US FDA inspection from January 28 to February 10, 2026, during which a 'Form 483' was issued with 9 observations. The FDA has concluded that this inspection is now closed, indicating no further regulatory action is required.

Governance Negative

2026-05-04 18:14

CRITICAL RED FLAG DETECTED

Aurobindo Pharma Limited announced the resignation of Dr. Sanjay Chaturvedi as Chief Executive Officer of Apitoria Pharma Private Limited, its wholly-owned subsidiary. Dr. Chaturvedi's resignation is effective from the close of business hours on May 4, 2026, as he is moving on to a different opportunity.

Business Update Positive

2026-05-01 13:59

Aurobindo Pharma's wholly-owned subsidiary, CuraTeQ Biologics, has received Health Canada's Notice of Compliance (NOC) for Bevqolva™, its bevacizumab biosimilar. This authorization grants formal marketing rights in Canada for the product, used to treat various cancers, including colorectal and lung. Bevqolva™ had previously secured marketing authorization from the MHRA and launched commercially in the UK in 2025. CuraTeQ Biologics also has two additional biosimilar applications under review by Health Canada.

Routine Neutral

2026-04-30 17:12

New Filing detected. See link for details.

Routine Neutral

2026-04-21 16:04

New Filing detected. See link for details.

Routine Neutral

2026-04-17 18:40

New Filing detected. See link for details.

Business Update Positive

2026-04-17 10:41

Aurobindo Pharma announced on April 17, 2026, receiving USFDA approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The product, with an estimated market size of US$ 50.2 million, will be launched immediately.

Business Update Positive

2026-04-15 16:09

Aurobindo Pharma's subsidiary, TheraNym Biologics, signed an additional product schedule with Merck Sharpe & Dohme (MSD), expanding an existing CMO agreement. TheraNym will invest USD 150-175 million to build a new Drug Substance manufacturing facility (Unit 2) with 60 KL bioreactor capacity for biologicals.

Routine Neutral

2026-04-09 16:25

New Filing detected. See link for details.

Routine Neutral

2026-04-08 11:42

New Filing detected. See link for details.

Business Update Positive

2026-04-07 18:18

Aurobindo Pharma received USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets for type-2 diabetes. The product has an estimated market size of US$ 514 million, and Aurobindo is eligible for 180 days of shared generic drug exclusivity.

Business Update Positive

2026-04-07 18:16

Aurobindo Pharma received USFDA final approval for Dapagliflozin Tablets (5 mg and 10 mg), a generic equivalent of Farxiga, for type-2 diabetes. The approved product has an estimated market size of US$10.2 billion and Aurobindo Pharma is eligible for 180 days of shared generic drug exclusivity.

Business Update Positive

2026-04-06 16:03

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive top-line results for its Phase 3 study of Omalizumab Biosimilar BP11. The study met all primary endpoints, showing high comparability, and regulatory filings with EMA and FDA are planned by the end of Q2 2026.

Ownership Positive

2026-04-06 09:00

Aurobindo Pharma's Board approved a share buyback of up to 54,23,728 equity shares (0.93% of total equity) at ₹1,475 per share, totaling up to ₹800 crores. The Record Date for determining eligible shareholders is April 17, 2026.

Business Update Positive

2026-04-06 08:33

Aurobindo Pharma's Board approved transferring its domestic branded generic pharmaceutical formulations business to wholly-owned subsidiary Auropharm Limited for ₹143.21 Cr. The strategic move aims to streamline and accelerate domestic business for faster growth and operational efficiency. The Business Transfer Agreement was executed on April 6, 2026.

Business Update Positive

2026-04-06 08:30

Aurobindo Pharma's Board approved a share buyback of up to 54.23 lakh shares (0.93% of paid-up capital) at ₹1,475 per share, totaling ₹800 crore. The Record Date for determining entitlement is April 17, 2026.

Business Update Neutral

2026-03-30 17:44

Aurobindo Pharma updated on acquiring 26% stake in Swarnaakshu Solar Power and a captive solar power purchase agreement. Completion, originally by March 31, 2026, is now expected by June 30, 2026, subject to state government approval for the captive solar power plant.

Governance Positive

2026-03-30 12:22

Aurobindo Pharma's postal ballot resulted in the approval of Dr. Punita Kumar Sinha's appointment as an Independent Director for 3 years (Feb 9, 2026 - Feb 8, 2029) with a 98.96% majority.

Business Update Positive

2026-03-25 16:58

Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has entered into a marketing and distribution agreement with STADA Arzneimittel AG for two EMA-approved biosimilars in EU territories, including France and Germany. This strategic partnership aims to expand market reach and drive revenue growth.

Routine Neutral

2026-03-23 17:55

Aurobindo Pharma announced the closure of its trading window for designated persons from April 1, 2026, until 48 hours after the declaration of the Audited Financial Results for the financial year ending March 31, 2026. The Board Meeting date will be intimated later.

Business Update Positive

2026-03-20 10:01

Aurobindo Pharma's subsidiary, Apitoria Pharma, received a 'Voluntary Action Indicated' (VAI) classification from the US FDA for its Unit-V manufacturing facility, closing the inspection which initially resulted in 3 observations.

Business Update Negative

2026-03-17 16:27

CRITICAL RED FLAG DETECTED

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Limited's Unit-II, has received an 'Official Action Indicated' (OAI) classification from the US FDA following an inspection from Nov 3-14, 2025, which also resulted in a Form 483 with 9 observations. The company states it doesn't foresee any business impact.

Business Update Negative

2026-03-13 12:55

CRITICAL RED FLAG DETECTED

Aurobindo Pharma received an order on March 12, 2026, from the Principal Commissioner of Customs and Central Tax confirming a GST demand and penalty of Rs. 77.61 Cr each, related to excess IGST refunds and ITC issues. The company plans to appeal and states no material financial/operational impact.

Business Update Positive

2026-03-12 09:50

AUROBINDO PHARMA announced that the US FDA inspection of its subsidiary's Unit-IV (APL Healthcare Limited) from Dec 2025, which had 5 observations (Form 483), is now classified as 'Voluntary Action Indicated' (VAI) and closed.

Business Update Positive

2026-03-11 13:23

Aurobindo Pharma Limited announced that company officials will participate in an Analyst/Investor group plant visit on March 17, 2026, from 09:00 AM to 05:00 PM (IST) at Vizag & Kakinada. No unpublished price sensitive information is intended to be discussed.

Business Update Positive

2026-03-11 13:21

Aurobindo Pharma Limited officials will participate in an analyst/investor group plant visit on March 16, 2026, at Vizag & Kakinada. No unpublished price sensitive information is intended to be discussed during the interactions.

Business Update Neutral

2026-03-09 14:46

Aurobindo Pharma officials will participate in an investor meeting arranged by BofA on March 13, 2026, in Singapore. No unpublished price sensitive information is intended to be discussed.

Business Update Positive

2026-03-04 12:15

Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Limited, announced the launch of Pomalidomide Capsules (1, 2, 3, 4 mg) in the US market. This generic equivalent of Pomalyst® Capsules addresses an estimated market size of approximately US$ 3.3 billion.

Business Update Neutral

2026-03-02 12:18

Aurobindo Pharma Limited will participate in the Goldman Sachs India Pharma Corporate Days investor meeting on March 06, 2026. The meeting will be virtual/online, and no unpublished price sensitive information is intended to be discussed.

AUROPHARMA

Aurobindo Pharma Limited

Price Chart

Filing History

Unlock Full History